NEWS RELEASE
FOR IMMEDIATE RELEASE

COMPANY CONTACT:                           INVESTOR CONTACT:
Anthony J. Simonetta                       Hayden Communications
Chief Financial Officer                    Brett Maas  (brett@haydenir.com)
(302) 456-6789                             Matt Hayden (matt@haydenir.com)
www.sdix.com                               (843) 272-4653
- -------------

        STRATEGIC DIAGNOSTICS RECEIVES NASDAQ STAFF DETERMINATION LETTER

NEWARK, DEL., NOVEMBER 22, 2005 - STRATEGIC DIAGNOSTICS INC. (NASDAQ: SDIX) - a
leading provider of biotechnology-based detection solutions for a broad range of
food, water, agricultural, industrial, environmental and scientific
applications, announced today that, as expected, on November 21, 2005, the
Company received the customary Nasdaq Staff Determination letter stating that
the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(14)
because the Company has not timely filed its Quarterly Report on Form 10-Q for
the period ended September 30, 2005, and that the Company's common stock is
therefore subject to delisting from The Nasdaq National Market. As a result of
the Company's filing delinquency, the letter "E" will be added to the Company's
trading symbol at the opening of business on November 23, 2005.

The Company has requested a hearing before a Nasdaq Listing Qualifications Panel
to review the Staff Determination. The request for the hearing will stay the
delisting until a decision is made by the Nasdaq Listing Qualifications Panel
after the hearing. A hearing is typically scheduled from 30 to 45 days after the
date the notification is issued. However, the Company cannot provide any
assurance that the Panel will grant its request for continued listing on The
Nasdaq National Market.

As previously announced, the delay in filing Form 10-Q is the result of the
Company continuing to discuss its policy regarding revenue recognition for
certain custom antibody arrangements and the methodology to be used to alter
such policy with the staff of the U.S. Securities and Exchange Commission. The
Company is devoting all necessary resources to resolving this matter as soon as
practicable, with the goal of doing so by the date of the hearing with the
Nasdaq Listing Qualifications Panel. The Company will schedule a conference call
to discuss this matter once the outcome is determined.

ABOUT STRATEGIC DIAGNOSTICS INC.
Strategic Diagnostics Inc. develops, manufactures and markets
biotechnology-based detection solutions to a diverse customer base, across
multiple industrial and human health markets. By applying its core competency of
creating custom antibodies to assay development, the Company produces unique,
sophisticated diagnostic testing and reagent systems that are responsive to
customer diagnostic and information needs. Customers benefit with quantifiable
"return on investment" by reducing time, labor, and/or material costs. All this
is accomplished while increasing accuracy, reliability and actionability of
essential test results. The Company is focused on sustaining this competitive
advantage by leveraging its expertise in immunology, proteomics,
bio-luminescence and other bio-reactive technologies to continue its successful
customer-focused research and development efforts. Recent innovations in high
throughput production of antibodies from genetic antigens will complement the
Company's established leadership in commercial and custom antibody production
for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and
position the Company for broader participation in the pharmacogenomics market.


This news release contains forward-looking statements reflecting SDI's current
expectations. When used in this press release, the words "anticipate", "could",
"enable", "estimate", "intend", "expect", "believe", "potential", "will",
"should", "project" "plan" and similar expressions as they relate to SDI are
intended to identify said forward-looking statements. Investors are cautioned
that all forward-looking statements involve risks and uncertainties, which may
cause actual results to differ from those anticipated by SDI at this time. Such
risks and uncertainties include, without limitation, changes in demand for
products, delays in product development, delays in market acceptance of new
products, retention of customers and employees, adequate supply of raw
materials, the successful integration and consolidation of the Maine production
facilities, inability to obtain or delays in obtaining fourth party, including
AOAC, or required government approvals, the ability to meet increased market
demand, competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described in
SDI's public filings with the U.S. Securities and Exchange Commission.

                                      # # #